MemoryGel乳房假体10年随访最终安全性与有效性结果
该前瞻性多中心临床研究纳入初次隆乳、修正隆乳、初次重建和修正重建患者,随访10年。结果显示Baker III/IV级包膜挛缩、感染、取出、破裂和再手术的10年累积发生率因适应证而异,证实MemoryGel假体在隆乳或重建中安全有效。
要点
- 初次隆乳10年包膜挛缩率12.1%,修正隆乳24.4%,初次重建20.5%,修正重建36.9%。
- 初次隆乳10年破裂率24.2%,初次重建32.7%,修正重建38.7%。
- 任何再手术率初次隆乳25.5%,修正重建达50.7%。
核心结论
- MemoryGel假体在隆乳或重建女性中安全有效。
研究设计与样本
- 前瞻性多中心临床研究,纳入初次隆乳552例、修正隆乳145例、初次重建251例、修正重建60例。
主要发现
- Baker III/IV级包膜挛缩10年累积发生率:初次隆乳12.1%,修正隆乳24.4%,初次重建20.5%,修正重建36.9%。
- 感染10年累积发生率:初次隆乳1.6%,修正隆乳1.4%,初次重建6.2%,修正重建0%。
- 取出伴或不伴更换10年累积发生率:初次隆乳11.6%,修正隆乳24.1%,初次重建33.4%,修正重建37.8%。
- 破裂10年累积发生率:初次隆乳24.2%,修正隆乳23.7%,初次重建32.7%,修正重建38.7%。
- 任何再手术10年累积发生率:初次隆乳25.5%,修正隆乳43.6%,初次重建49.0%,修正重建50.7%。
临床怎么用
- 可为患者提供不同适应证下10年累积并发症风险的具体数据用于术前咨询。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mentor MemoryGel Breast Implants were approved by the U.S. Food and Drug Administration in November of 2006. Patients in the Core clinical study supporting this approval were followed for 10 years. METHODS: This prospective, multicenter, clinical study included primary augmentation, revision augmentation, primary reconstruction, and revision reconstruction patients implanted with smooth or Siltex Texture MemoryGel Implants. Incidence, severity, and method of resolution for all postoperative complications were assessed on per-patient and per-implant bases. The primary effectiveness endpoints were overall mean change in chest circumference and bra cup size following the implantation procedure. RESULTS: Primary augmentation (n = 552), revision augmentation (n = 145), primary reconstruction (n = 251), and revision reconstruction (n = 60) patients were enrolled in the study. Kaplan-Meier estimated 10-year cumulative incidence rates for key complications at the subject level for Baker grade III/IV capsular contracture were as follows: primary augmentation, 12.1 percent; revision augmentation, 24.4 percent; primary reconstruction, 20.5 percent; and revision reconstruction, 36.9 percent. For infection, rates were as follows: primary augmentation, 1.6 percent; revision augmentation, 1.4 percent; primary reconstruction, 6.2 percent; and revision reconstruction, 0 percent. For explantation with or without replacement, rates were as follows: primary augmentation, 11.6 percent; revision augmentation, 24.1 percent; primary reconstruction, 33.4 percent; and revision reconstruction; 37.8 percent. For rupture, rates were as follows: primary augmentation, 24.2 percent; revision augmentation, 23.7 percent; primary reconstruction, 32.7 percent; and revision reconstruction, 38.7 percent. For any reoperation, rates were as follows: primary augmentation, 25.5 percent; revision augmentation, 43.6 percent; primary reconstruction, 49.0 percent; and revision reconstruction, 50.7 percent. CONCLUSION: The results of this study demonstrate that MemoryGel Implants are safe and effective for use in women undergoing breast augmentation or reconstruction. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
引用
- Caplin DA, Calobrace MB, Wixtrom RN, et al. MemoryGel Breast Implants: Final Safety and Efficacy Results after 10 Years of Follow-Up. Plast Reconstr Surg. 2021. PMID: 33620918. doi:10.1097/PRS.0000000000007635
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。